Completed PHASE4 INTERVENTIONAL 2-arm NCT00896168

An Efficacy and Safety Study of Infliximab in Participants With Rheumatoid Arthritis

A Multi-Center, Pre-Marketing Clinical Trial to Evaluate the Efficacy and Safety of Infliximab Treatment on Rheumatoid Arthritis

Sponsor: Xian-Janssen Pharmaceutical Ltd.

Conditions Arthritis, Rheumatoid

Interventions Infliximab Methotrexate

Updated 6 times since 2017 Last updated: Sep 11, 2013 Started: Jun 30, 2007 Primary completion: Apr 30, 2008 Completion: Apr 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00896168, this PHASE4 trial focuses on Arthritis, Rheumatoid and remains completed. Sponsored by Xian-Janssen Pharmaceutical Ltd., it has been updated 6 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Xian-Janssen Pharmaceutical Ltd.

Data source: Xian-Janssen Pharmaceutical Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.